Items

Estimation of lipophilicity data for derivatives of alkandiamine-N,N'-di-2-(3-cyclohexyl)propanoic acid with potential antineoplastic activity, UHPLC-MS method (2017-03)

B. Tubić, B. Marković, S. Vladimirov, A. Savić, J. Poljarević, T. Sabo, Estimation of lipophilicity data for derivatives of alkandiamine-N,N'-di-2-(3-cyclohexyl)propanoic acid with potential antineoplastic activity, UHPLC-MS method, IFMBE Proceedings 2017 (62), pp. 402 - 409, Mar, 2017

Inter-laboratory reproducibility of bioanalytical UHPLC-MS/MS method (2017-06)

B. Tubić, S. Vladimirov, B. Marković, Inter-laboratory reproducibility of bioanalytical UHPLC-MS/MS method, TOTAL QUALITY MANAGEMENT - ADVANCED AND INTELLIGENT APPROACHES - PROCEEDINGS, pp. 59 - 63, Jun, 2017

Inter-laboratory reproducibility of bioanalytical UHPLC-MS/MS method (2017-06)

B. Tubić, S. Vladimirov, B. Marković, Inter-laboratory reproducibility of bioanalytical UHPLC-MS/MS method, International Journal of advanced quality, pp. 49 - 53, Jun, 2017

In vitro/in silico characterisation of novel substances with cytotoxic activity: 1,2-ethanediamine-N,N'-di-2-(3-cyclohexyl)propanoic acid and 1,3-propanediamine-N,N'-di-2-(3-cyclohexyl)propanoic acid derivatives (2017-09)

B. Tubić, B. Marković, J. Vučković, V. Dobričić, S. Vladimirov, In vitro/in silico characterisation of novel substances with cytotoxic activity: 1,2-ethanediamine-N,N'-di-2-(3-cyclohexyl)propanoic acid and 1,3-propanediamine-N,N'-di-2-(3-cyclohexyl)propanoic acid derivatives, Book of abstracts of the Conference on the 65th Anniversary of Faculty of Pharmacy, pp. 21 - 22, Sep, 2017

HPLC determination of benzaldehyde in benzyl alcohol containing injectable formulations (2017-10)

A. Uzunović, S. Pilipović, B. Tubić, A. Sapčanin, I. Tahirović, HPLC determination of benzaldehyde in benzyl alcohol containing injectable formulations, Acta Pharmaceutica Hungarica – 7th BBBB Edition, pp. 3 - 4, Oct, 2017

Fizičko‐hemijska i ADME karakterizacija analoga estara etilendiamin‐N,N’‐di‐2‐(3‐cikloheksil)propanske kiseline sa potencijalnim citotoksičnim dejstvom (2018-10)

B. Tubić, B. Marković, S. Vladimirov, V. Dobričić, J. Poljarević, A. Savić, T. Sabo, Fizičko‐hemijska i ADME karakterizacija analoga estara etilendiamin‐N,N’‐di‐2‐(3‐cikloheksil)propanske kiseline sa potencijalnim citotoksičnim dejstvom, Arhiv za farmaciju 2018;68, pp. 106 - 107, Oct, 2018

Primena PAMPA tehnike i QSPR analize u proceni gastrointestinalne apsorpcije i dizajniranju novih biološki aktivnih jedinjenja (2018-10)

V. Dobričić, J. Savić, B. Tubić, K. Nikolić, J. Brborić, B. Marković, O. Čudina, Primena PAMPA tehnike i QSPR analize u proceni gastrointestinalne apsorpcije i dizajniranju novih biološki aktivnih jedinjenja, Arhiv za farmaciju 2018;68, pp. 112 - 113, Oct, 2018

Uticaj pravilnika kojim se regulišu maksimalne veleprodajne cijene lijekova na cijene lijekova u Bosni i Hercegovini (2018-10)

B. Tubić, J. Aničić, T. Spasojević, A. Cvijanović, A. Zolak, Uticaj pravilnika kojim se regulišu maksimalne veleprodajne cijene lijekova na cijene lijekova u Bosni i Hercegovini, Arhiv za farmaciju 2018;68, pp. 277 - 278, Oct, 2018

Bosnia and Herzegovina take brave steps in pharmacovigilance, Signals of Current Interest (2018-11)

B. Tubić, Bosnia and Herzegovina take brave steps in pharmacovigilance, Signals of Current Interest, Signals of Current Interest, pp. 25 - 25, Nov, 2018

Sličnosti i razlike ciljane terapije u tretmanu malignih oboljenja – nibovi versus mabovi (2018-11)

B. Tubić, Sličnosti i razlike ciljane terapije u tretmanu malignih oboljenja – nibovi versus mabovi, Zbornik radova, pp. 15 - 19, Nov, 2018

Utjecaj Pravilnika kojim se reguliraju maksimalne veleprodajne cijene lijekova na cijene lijekova u Bosni i Hercegovini (2019-04)

J. Aničić, A. Zolak, B. Tubić, T. Spasojević, A. Cvijanović, Utjecaj Pravilnika kojim se reguliraju maksimalne veleprodajne cijene lijekova na cijene lijekova u Bosni i Hercegovini, Knjiga sažetaka, 2019, pp. 177 - 177, Apr, 2019

Specifičnosti potrošnje antimikrobnih lijekova u Bosni i Hercegovini (2019-04)

T. Spasojević, B. Tubić, A. Cvijanović, A. Zolak, Specifičnosti potrošnje antimikrobnih lijekova u Bosni i Hercegovini, Knjiga sažetaka, 2019, pp. 245 - 245, Apr, 2019

Discovery of membrane permeability, pharmacokinetics properties and mechanism of action for analogs of ethylenediamine-N,N’-di-2-(3-cyclohexyl)propionic acid and 1,3-propandiamine-N,N’-di-2-(3-cyclohexyl)propionic acid with antiproliferative activity using in vitro and in silico methods (2019-05)

B. Tubić, B. Marković, T. Sabo, Discovery of membrane permeability, pharmacokinetics properties and mechanism of action for analogs of ethylenediamine-N,N’-di-2-(3-cyclohexyl)propionic acid and 1,3-propandiamine-N,N’-di-2-(3-cyclohexyl)propionic acid with antiproliferative activity using in vitro and in silico methods, CMBEBIH 2019, Springer, Proceedings of the International Conference on Medical and Biological Engineering, 16–18 May 2019 Banja Luka, Bosnia and Herzegovina, pp. 357 - 369, May, 2019

Challenges in authorization and administration of biological drugs and biosimilars in Bosnia and Herzegovina (2019-09)

B. Tubić, S. Kecman, R. Škrbić, L. Nježić, N. Stojaković, S. Goločorbin Kon, M. Mikov, Challenges in authorization and administration of biological drugs and biosimilars in Bosnia and Herzegovina, ABSTRACT BOOK, pp. 95 - 96, Sep, 2019

DRUG MARKET IN BOSNIA AND HERZEGOVINA – TO WHAT EXTENT THE PHARMACEUTICAL INDUSTRY IS IN LINE WITH THE POPULATION’S NEEDS (2019-09)

S. Kecman, B. Tubić, R. Škrbić, N. Stojaković, L. Nježić, S. Goločorbin Kon, M. Mikov, DRUG MARKET IN BOSNIA AND HERZEGOVINA – TO WHAT EXTENT THE PHARMACEUTICAL INDUSTRY IS IN LINE WITH THE POPULATION’S NEEDS, ABSTRACT BOOK, pp. 265 - 266, Sep, 2019

INHIBITORI EGFR U TERAPIJI NSCLC (2019-10)

B. Tubić, INHIBITORI EGFR U TERAPIJI NSCLC, Knjiga sažetaka, pp. 160 - 161, Oct, 2019

Estimation of lipophilicity data for derivatives of alkandiamine-N,N'-di-2-(3-cyclohexyl)propanoic acid with potential antineoplastic activity, UHPLC-MS method (2017-03)

Inter-laboratory reproducibility of bioanalytical UHPLC-MS/MS method (2017-06)

Inter-laboratory reproducibility of bioanalytical UHPLC-MS/MS method (2017-06)

In vitro/in silico characterisation of novel substances with cytotoxic activity: 1,2-ethanediamine-N,N'-di-2-(3-cyclohexyl)propanoic acid and 1,3-propanediamine-N,N'-di-2-(3-cyclohexyl)propanoic acid derivatives (2017-09)

HPLC determination of benzaldehyde in benzyl alcohol containing injectable formulations (2017-10)

Fizičko‐hemijska i ADME karakterizacija analoga estara etilendiamin‐N,N’‐di‐2‐(3‐cikloheksil)propanske kiseline sa potencijalnim citotoksičnim dejstvom (2018-10)

Primena PAMPA tehnike i QSPR analize u proceni gastrointestinalne apsorpcije i dizajniranju novih biološki aktivnih jedinjenja (2018-10)

Uticaj pravilnika kojim se regulišu maksimalne veleprodajne cijene lijekova na cijene lijekova u Bosni i Hercegovini (2018-10)

Bosnia and Herzegovina take brave steps in pharmacovigilance, Signals of Current Interest (2018-11)

Sličnosti i razlike ciljane terapije u tretmanu malignih oboljenja – nibovi versus mabovi (2018-11)

Utjecaj Pravilnika kojim se reguliraju maksimalne veleprodajne cijene lijekova na cijene lijekova u Bosni i Hercegovini (2019-04)

Specifičnosti potrošnje antimikrobnih lijekova u Bosni i Hercegovini (2019-04)

Challenges in authorization and administration of biological drugs and biosimilars in Bosnia and Herzegovina (2019-09)

DRUG MARKET IN BOSNIA AND HERZEGOVINA – TO WHAT EXTENT THE PHARMACEUTICAL INDUSTRY IS IN LINE WITH THE POPULATION’S NEEDS (2019-09)

INHIBITORI EGFR U TERAPIJI NSCLC (2019-10)

MOLEKULARNA POZADINA NAJČEŠĆIH NUSPOJAVA U BOSNI I HERCEGOVINI (2019-10)

Cardiovascular toxicity of antineoplastic medicines in Bosnia and Herzegovina (2020)

Antioxidant activity of Lamiaceae teas prepared in household (2023)

Poljoprivreda i prehrambena industrija BiH u uslovima globalizacije i institucionalizacije (2007)